Edward Kim, MD of Levine Cancer Institute explains how anti-PD-L1 and PD-1 therapies are being combined with chemotherapy and targeted therapies in treating lung cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.
Advertisement
Advertisement